Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

ISAR-REACT 5: Prasugrel superior to ticagrelor in ACS

Publish date:: September 17, 2019

Key clinical point: Prasugrel proved superior to ticagrelor in the setting of acute coronary syndrome with a planned invasive strategy.

Major finding: The 1-year composite of death, acute MI, or stroke occurred in 9.3% of patients randomized to ticagrelor and 6.9% of those assigned to prasugrel, a statistically significant, clinically meaningful, and totally unexpected difference.

Study details: This was a multicenter trial including 4,018 acute coronary syndrome patients with a planned invasive approach who were randomized to ticagrelor or prasugrel.

Disclosures: The presenter reported having no financial conflicts regarding the ISAR-REACT 5 study, sponsored by the German Heart Center and the German Center for Cardiovascular Research.

Citation:

Schuepke S et al. N Engl J Med. 2019 Sep 1. doi: 10.1056/NEJMoa1908973.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Annual WCC visits significantly limit asthma worsening,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Microplastics permeate human placentas,

Must Reads in Cardiology

Sac/val heart failure benefit extends to diabetes patients,

Sedentary postmenopausal women have higher heart failure risk,

Experts disagree with USPSTF’s take on pediatric blood pressure screening,

GALACTIC-HF: New ‘myotropic’ drug class shows modest HFrEF benefit,

Don’t miss cardiovascular risk factors in transgender patients,